Kynurenine monooxygenase regulates inflammation during critical illness and recovery in experimental acute pancreatitis
Mice, Knockout
Inflammation
acute pancreatitis
multiple organ failure
QH301-705.5
Critical Illness
Multiple Organ Failure
3-hydroxykynurenine
metabolomics
CP: Metabolism
3. Good health
kynurenine 3-monooxygenase
Mice
Kynurenine 3-Monooxygenase
Pancreatitis
Metabolism [CP]
Acute Disease
critical illness
Animals
Biology (General)
transcriptome
Kynurenine
DOI:
10.1016/j.celrep.2023.112763
Publication Date:
2023-07-19T22:17:54Z
AUTHORS (20)
ABSTRACT
Kynurenine monooxygenase (KMO) blockade protects against multiple organ failure caused by acute pancreatitis (AP), but the link between KMO and systemic inflammation has eluded discovery until now. Here, we show that the KMO product 3-hydroxykynurenine primes innate immune signaling to exacerbate systemic inflammation during experimental AP. We find a tissue-specific role for KMO, where mice lacking Kmo solely in hepatocytes have elevated plasma 3-hydroxykynurenine levels that prime inflammatory gene transcription. 3-Hydroxykynurenine synergizes with interleukin-1β to cause cellular apoptosis. Critically, mice with elevated 3-hydroxykynurenine succumb fatally earlier and more readily to experimental AP. Therapeutically, blockade with the highly selective KMO inhibitor GSK898 rescues the phenotype, reducing 3-hydroxykynurenine and protecting against critical illness and death. Together, our findings establish KMO and 3-hydroxykynurenine as regulators of inflammation and the innate immune response to sterile inflammation. During critical illness, excess morbidity and death from multiple organ failure can be rescued by systemic KMO blockade.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (69)
CITATIONS (14)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....